sodium phenylbutyrate

This medicine is authorised for use in the European Union.


This is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).

This EPAR was last updated on 16/12/2022

Authorisation details

Product details
Agency product number
Active substance
Sodium phenylbutyrate
International non-proprietary name (INN) or common name
sodium phenylbutyrate
Therapeutic area (MeSH)
  • Ornithine Carbamoyltransferase Deficiency Disease
  • Citrullinemia
  • Carbamoyl-Phosphate Synthase I Deficiency Disease
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Immedica Pharma AB
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Solnavagen 3H
113 63 Stockholm

Product information

12/12/2022 Ammonaps - EMEA/H/C/000219 - IAIN/0063

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other alimentary tract and metabolism products

Therapeutic indication

Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or
argininosuccinate synthetase.

It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease
(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating
1 rating